Alzheimer’s Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AD space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Forecast updates will be triggered by key market-impacting events.

Key Highlights Include:

• Potential first humanized monoclonal antibody for the treatment of AD could enter in the market in 2021.
  
• Approval and launch of DMT classes will revolutionize the field of AD therapeutics, regardless of their cost and increase competition.
  
• Three of BACE1 inhibitors have been terminated since September 2017 so elenbecestat is now leading this class due to recently published positive data results.
  
• Combination of treatment with CNP520 and CAD106 from Novartis could open new option for the treatment of AD.
  
• Launch of four new pipeline drugs added in the late stage pipeline.
  

Components of the slide deck include:

• Key clinical trial landscape updates
  
• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  
• Overview of updates to the forecast model based on anticipated future impact of events
  
• Forward-looking events calendar listing expected key updates to the AD competitive space through October2018-October 2021